Gene expression profiling has the potential to offer consistent, objective diagnostic test results once a standardized protocol has been established. We investigated the robustness, precision, and reproducibility of microarray technology.
Microarray analysis has been used in multiple studies to identify differentially expressed genes associated with distinct clinical and therapeutically relevant classes of leukemias (1) (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) . The data are limited, however, on the actual robustness and performance of gene expression profiling for detailed diagnostic workups, not only for both acute and chronic leukemias in particular but also for the broader use of microarray technology in a clinical laboratory setting. As a prerequisite to the application of these approaches, sample-preparation procedures must be adequately standardized and simplified for routine use in a clinical laboratory. In addition, the classification performance of microarray assays must be proved in prospective studies that incorporate both separate and adequately powered independent patient cohorts for algorithm development and validation (15 ) .
Thus far, variables such as shipment time and isolation procedures for total RNA have been shown not to substantially influence the underlying diagnostic gene expression signatures in a patient sample, and such procedures have led to robust results (16, 17 ) . Such information does not abrogate the need for carefully designed clinical research studies, because preanalytical variables are known to influence gene expression profiles, as has been demonstrated for various types of sample-purification and cell-fractionation techniques (18 -21 ) . Therefore, consensus guidelines for microarray gene expression analyses, such as those published by 3 hematology networks (the International BFM Study Group, the German Competence Network "Acute and Chronic Leukemias," and the European LeukemiaNet), are helpful but represent just a starting point for the task of incorporating molecular profiling into clinical practice (22, 23 ) .
We report the technical precision of gene expression signatures after analyzing quadruplicate lysates of mononuclear cells from leukemia patients and control individuals on a customized microarray designed for the subclassification of leukemias (24 ) . After central collection and diagnostic workup of 160 individual patient samples representing 11 distinct leukemia subclasses, myelodysplastic syndromes, and nonleukemia controls, a baseline microarray analysis was performed in a hematology laboratory experienced with this technology. Three additional identical sets of replicate samples were then blinded and shipped to 3 independent laboratories to repeat the analyses of these biological samples and to assess the reproducibility of microarray analysis.
Materials and Methods

STUDY DESIGN
One hundred sixty different samples of bone marrow (n ϭ 115) or peripheral blood (n ϭ 45) were obtained from individual untreated patients in the Munich Leukemia Laboratory (see Table S1 in the Data Supplement that accompanies the online version of this article at http://www.clinchem.org/content/vol54/issue10). All patients gave their informed consent for participation after having been advised of the purpose and investigational nature of the study. The study design adhered to the tenets of the Declaration of Helsinki and was approved before its initiation by the ethics committees of the participating institutions. The diagnostic workup of leukemia was performed in Munich, Germany, as previously described (25) (26) (27) (28) (29) (30) (31) . Full sample details are given in the online Data Supplement. For gene expression analysis, mononuclear cells were purified with Ficoll density-gradient centrifugation, and replicate lysates of 5 ϫ 10 6 cells each were prepared (Buffer RLT; Qiagen). Four replicates of the mononuclear cell lysates were prepared for each patient. Each participating laboratory (in Basel, Linz, Geneva, and Munich) was provided with one frozen mononuclear cell lysate from each patient for microarray analysis. Each participating laboratory designated specific operators for conducting the study. Three of the 4 laboratories had no previous experience with the Affymetrix gene expression microarray sample-preparation assay (Linz, Basel, and Geneva). Thus, the operators in these laboratories were introduced to this technology in a 5-day training course on a standardized sample-preparation protocol for microarray analysis that used commercially available total RNA from cancer cell lines MCF-7 and HepG2 (Ambion). Furthermore, each participating center was provided with identical laboratory supplies and equipment for microarray analysis, including reagent kits, enzymes, spectrophotometers, and heat block instruments.
MICROARRAY ANALYSIS
After shipment on dry ice, total RNA was extracted from the homogenized patient lysates and processed with a previously described protocol (RNeasy Kit; Qiagen) at each laboratory between March and August 2007 (16 ) . The Affymetrix HG-U133 Plus 2.0 microarrays were used for training the operators in the assay, and the custom AmpliChip Leukemia research microarray (Roche Molecular Systems) was used for patient samples. The AmpliChip Leukemia research microarray was specifically designed for the classification of leukemias (32 ) . The chip contains 1 480 distinct probe sets with an 11-m feature size. Of these probe sets, 1 457 are used for generating normalized signal intensities of disease-related genes; the remaining 23 probe sets interrogate control sequences and housekeeping genes. Full details of the sample-preparation workflow, as well as a gene-by-gene ANOVA of the custom microarray probe sets, are given in data files in the online Data Supplement.
QUALITY REPORT AND STATISTICAL METHODS
A total of 637 AmpliChip Leukemia microarray gene expression profiles were included in the analysis. A detailed data-quality report was generated for each gene expression profile to define the overall quality of each microarray experiment (see the online Data Supplement). The quality thresholds for passing the study's quality criteria were defined as: (a) a purified total-RNA amount of Ͼ1.0 g per sample, (b) a cRNA yield for each target preparation of Ͼ8.0 g, (c) a percentage of probe sets called as present of Ͼ20% (33 ) , and (d) a scaling factor of Ͻ10.0.
Preprocessing the data for imaging included a summarization and quantile-normalization step to generate probe set-level signal intensities for each microarray experiment; this step was performed as previously described (34 ) . The expression signals of a microarray were normalized to the quantiles of a predefined distribution (␤ distribution with parameters P ϭ 1.2 and q ϭ 3). To assess the interlaboratory consistency and reproducibility of the gene expression microarray analysis, we generated Bland-Altman plots (35 ) . To assess whether systematic differences in total-RNA and cRNA yields existed among centers, we performed a repeated-measures regression analysis for each yield variable as an outcome. We assumed an unstructured covariance structure common to each individual, allowing for different variances for each center and different covariances between each pair of centers. We further assumed that yields from different patient samples were uncorrelated. Tests of means of yields were performed with variances estimated with this model, and P values were corrected with the Bonferroni correction for multiple testing.
Data visualization and exploratory analyses, such as box plots, unsupervised hierarchical clustering, and principal components analysis, were performed with R software versions 2.4.1 and 2.5.1 (http://www.Rproject.org), which included the affy, made4, and Heatplus packages (36 ) . The repeated-measures analysis was performed with SAS version 9.1 and the PROC MIXED analysis routine (SAS Institute). All microarray data are available in files in the online Data Supplement.
Results
ASSESSMENT OF SAMPLE-PREPARATION QUALITY
Upon receipt of the mononuclear cell lysates, each of the participating laboratories purified comparable amounts of total RNA from the 160 quadruplicate samples ( Fig. 1A ; detailed summary in the online Data Supplement). At least 1.0 g of total RNA was obtained from 637 (99.5%) of the 640 preparations. Table S2 in the online Data Supplement summarizes the estimates of variance, ranges (minimum, maximum), and median total-RNA yields for each of the 4 centers. The 4 laboratories isolated a mean of 7.2 g, 7.5 g, 7.6 g, and 8.2 g of total RNA from mononuclear cells. Three preparations from one center failed to yield total-RNA amounts adequate for microarray analyses (Table S3 in the online Data Supplement). The laboratory in Munich produced slightly higher total-RNA yields than the other 3 laboratories.
We next assessed the impact of the input total-RNA quantity on overall assay performance and consistency across laboratories. The current version of the sample-preparation protocol does not specify a fixed total-RNA amount but rather permits a total-RNA input range of 1.0 -8.0 g for the cDNA-synthesis step. Fig. 1B shows that the 4 laboratories used varying amounts of total RNA for cDNA synthesis. For example, the Linz center intentionally added no more than 3.0 g total RNA into the sample-preparation workflow, yet the cRNA yields from this center were comparable to those of the other centers (Fig. 1C) . Of the 637 processed total-RNA samples, 622 (97.6%) produced successful in vitro transcription reactions, i.e., a cRNA yield Ͼ8.0 g. Table S2 in the online Data Supplement summarizes the variance estimates, ranges, and medians for cRNA yields obtained from each of the 4 centers. Fifteen preparations from 11 patient lysates produced Ͻ8.0 g of cRNA and thus were considered as failed preparations (see Table S4 in the online Data Supplement). Although the preparation for one sample (no. 112) failed in the majority of the laboratories, those for the other samples failed primarily in one of the 4 centers.
Finally, the recommended cRNA target amount of 11.0 g for the fragmentation assay was achieved for most samples (Fig. 1D ). For 40 patient samples (58 sample preparations total), Ͻ11.0 g of cRNA was used as the input into the fragmentation step in preparation for hybridization to the microarray. The online Data Supplement lists the cRNA amounts for the individual samples.
ASSESSMENT OF SAMPLE-PREPARATION REPRODUCIBILITY
Bland-Altman analyses were performed to investigate whether systematic differences in total-RNA yields existed among laboratories for the same sample (Fig. 2) . For example, each dot in the comparison of the Munich and Geneva laboratory results represents a patient sample. The mean total yield in micrograms for the 2 total-RNA preparations on the x axis is plotted against the difference in micrograms between the 2 laboratories on the y axis. For this example, there is a 95% chance that measurements of the same sample from these 2 laboratories will be within 5.8 g of each other. This 95% interval of agreement ranged from Ϫ2.24 g to 3.55 g, with a mean interval of agreement of 0.65 g. More detailed information and raw values for all 6 pairwise comparisons of the centers are presented in Table S5 and Fig. 1A in the online Data Supplement. For all total-RNA comparisons, any 2 centers are expected to have no more than a 7.95-g difference in total-RNA yield for the same sample. The mean observed difference in total-RNA yield between 2 centers for a given patient sample ranged from 0.02 g to 1.03 g.
Similarly, we also generated Bland-Altman plots for the cRNA yields to investigate whether systematic differences in cRNA yields had arisen among laboratories for the same sample (Fig. 3) . For example, comparing the results for the Munich and Geneva laboratories shows that there is a 95% chance that measurements of the same sample from these 2 laboratories will be within 39.52 g of each other. This 95% interval of agreement ranged from Ϫ19.01 g to 20.51 g, with a mean interval of agreement of 0.75 g. More detailed information and raw values for all 6 pairwise comparisons of the centers are presented in Table S6 and Fig.  1B in the online Data Supplement. In summary, any 2 centers would be expected to have a difference in cRNA yield of Ͻ49.38 g for the same sample. The mean observed difference between 2 centers in total-RNA yield for a given patient sample ranged from 0.40 g to 6.18 g.
ASSESSMENT OF MICROARRAY DATA QUALITY
In further processing the sample replicates, we hybridized the 622 preparations with successful in vitro transcription reactions and adequate cRNA yields to AmpliChip Leukemia microarrays, and we evaluated various general microarray data-quality variables. Overall, all 4 laboratories generated very reproducible data sets with respect to the percentage of probe sets called as present, the scaling factor, and the ratio of the intensities of 3Ј probes to 5Ј probes for the housekeeping gene GAPDH 6 (glyceraldehyde-3-phosphate dehydrogenase) (Fig. 4) . In addition, we processed the 15 preparations from 11 patient lysates (lysate nos. 4, 26, 46, 67, 93, 102, 109, 112, 113, 122, and 146) with inadequate cRNA yields (Table S4 in the online Data Supplement) to microarrays to test whether the various sample-preparation cutoff criteria were useful predictors of subsequent microarray data of poor quality.
After their hybridization to microarrays, we detected a mean of 47.6%, 46.5%, 46.2%, and 46.4% of the probe sets as present at the Basel, Geneva, Linz, and Munich centers, respectively (Fig. 4A) . One sample consistently did not pass the probe-set call filter of Ͼ20.0% present. This sample (no. 112) also had previously not passed the cRNA-yield filter in the majority of the centers. As demonstrated in Fig. 4B , the data sets from the 4 laboratories also had comparable scaling factors, with mean values of 3.1, 3.7, 4.0, and 4.2 for the Basel, Geneva, Linz, and Munich centers, respectively. Again, sample no. 112 was different, with scaling factors clearly higher than the cutoff limit of 10.0. Two other samples from the Linz center also showed scaling factors Ͼ10.0, and these samples were examined in more detail. Both samples had low cRNA yields (2.6 g for sample no. 67; 4.3 g for sample no. 93) and thus usually would not have been recommended for hybridization to a microarray. In fact, these samples had almost identical total-RNA input amounts and cRNA yields after the in vitro transcription reaction. Sample no. 26 prepared by the Munich laboratory also had a scaling factor above the cutoff limit and at 13.3 g clearly had passed the recommended cRNA yield. This result indicates the need to carefully integrate several sample-preparation variables into a final quality result to decide whether a sample can be hybridized to a microarray.
Another QC variable, the so-called 3Ј/5Ј GAPDH ratio, is presented in Fig. 4C . The signal-intensity ratios of GAPDH probes located at both the 3Ј and 5Ј posi- Each Bland-Altman plot is a visual representation of the consistency of the total-RNA results between any 2 centers. For each comparison, the mean value of the 2 total-RNA purification results from a single patient sample at the 2 centers (x axis) is plotted against the absolute difference between the same 2 results (y axis). The solid horizontal line represents the overall mean of the differences, and the dashed lines show the range containing the mean of the differences Ϯ 2 SDs, which is referred to as the limits of agreement. Depicted in each plot are the data for 160 patient samples. Laboratory abbreviations: BAS, Basel; GEN, Geneva; LIN, Linz; MUC, Munich.
tions of the gene frequently are used as indicators of the integrity of the starting total RNA. Although the manufacturer has specified no absolute cutoff value, many microarray studies have referred to a ratio of Ͻ3.0 (23 ) . In the present study, 612 of 637 samples had ratios Ͻ3.0, and only 2 microarray data sets showed ratios Ͼ4.0. These results indicate the high quality of the starting material collected during the routine diagnostic workups.
A final microarray data-quality variable is the distribution of the CV within each laboratory for the quantile-normalized signals over all of the probe sets represented on the AmpliChip Leukemia microarray (Fig. 4D) . All participating laboratories generated remarkably comparable signal-intensity distributions after normalization, with mean (SD) values of 27.6% (1.5%), 27.5% (1.6%), 27.7% (1.5%), and 27.5% (1.5%) for the Basel, Geneva, Linz, and Munich laboratories, respectively.
INTERLABORATORY SIMILARITY IN GENE EXPRESSION PROFILES
We next investigated the similarity in the generated gene expression profiles with unsupervised hierarchical clustering. In total, 160 quadruplicates of mononuclear cell lysates were provided to the 4 laboratories. In 157 cases, quadruplicate gene expression profiles were Each Bland-Altman plot is a visual representation of the consistency between any 2 centers in the cRNA results. For each comparison, the mean value of the 2 cRNA purification results from a single patient sample at the 2 centers (x axis) is plotted against the absolute difference between the same 2 results (y axis). The solid horizontal line represents the overall mean of the differences, and the dashed lines show the range containing the mean of the differences Ϯ 2 SDs, which is referred to as the limits of agreement. Depicted in each plot are the data for 160 patient samples. Laboratory abbreviations: BAS, Basel; GEN, Geneva; LIN, Linz; MUC, Munich. generated in all of the centers. Of these cases, case no. 112 consistently showed low quality; therefore, all replicates from this sample were excluded from further analyses. Thus, of the 160 samples in this study, only 4 samples were excluded on the basis of these criteria, with each laboratory having shown failures. The hierarchical clustering analysis was based on 1 457 probe sets that were represented on the AmpliChip Leukemia microarray. As depicted in the unsupervised clustering dendrogram in Fig. 5 , the 156 quadruplicate samples are split into several major branches. A major branch was seen at the left, where all chronic lymphocytic leukemias (CLLs) grouped together (branch 1). Next to the CLL samples were 3 major branches that contained the majority of acute leukemias (branch 2), chronic myeloid leukemias (branch 3), and myelodysplastic syndromes and samples from nonleukemia patients (branch 4). In all cases, the quadruplicates for the individual patients were the most similar to each other and clustered together. There was no indication of any association between gene expression profiles due to different operators or laboratories. This finding is visualized more clearly in an enlarged section of the CLL branch (Fig. 5) . In addition, we performed principal components analyses as another way to visualize the similarity of profiles. As is shown in Fig. 6 , the individual gene expression profiles of the quadruplicates grouped closely together. As exemplified by the samples representing CLL, chronic myeloid leukemia, pro-B-cell acute lymphoblastic leukemia with t(11q23)/malignant lymphoma (lymphoblastic type), and acute myeloid leukemia with t(15;17), corresponding types of biological samples grouped according to their underlying similar- The unsupervised clustering of the gene expression profiles of all samples was performed with the 1 457 probe sets on the AmpliChip Leukemia microarray for the 624 experiments included in the study that passed the quality filter. We excluded sample nos. 65, 66, and 68 because they failed the total-RNA purification sample-preparation step at one center (Linz). Sample no. 112 was also excluded because it failed multiple microarray QC criteria at several centers. Quantile-normalized signals were used to cluster the profiles. The similarity of samples was computed by Euclidean distance, and Ward's method was then used to cluster the gene expression profiles on the basis of these measures. The upper part of the figure shows a dendrogram of all the samples. The algorithm identified 4 major branches that represent CLL (branch 1), the majority of acute leukemias (branch 2), chronic myeloid leukemias (branch 3), and myelodysplastic syndromes and samples from nonleukemia patients (branch 4). The lower part of the figure shows an enlarged section of the CLL branch. Each line is annotated by sample class, the laboratory site of the analysis, corresponding colored sample identifier, and sample type. The files in the online Data Supplement include a detailed worksheet that identifies and annotates the individual lines of the dendrogram. BAS, Basel; GEN, Geneva; LIN, Linz; MUC, Munich; AML, acute myeloid leukemia; MLL, malignant lymphoma, lymphoblastic type; c-ALL, childhood acute lymphoblastic leukemia; Pre-B-ALL, pre-B-cell acute lymphoblastic leukemia; CML, chronic myeloid leukemia; MDS, myelodysplastic syndrome; Pro-B-ALL, pro-B-cell ALL.
ity (Fig. 6A) but not according to the center where the microarray experiments were performed or the operators who performed the analyses (Fig. 6B) .
Finally, the relationships between gene expression profiles within sample types can be visualized by pairwise classification analyses, in which various sets of training data have been used to develop a classifier for distinguishing between the distinct leukemia subtypes (7, 24 ) . For example, when we applied a prediction algorithm to classify the 4 quadruplicates of sample no. 142 [a case of pro-B-cell acute lymphoblastic leukemia with t(11q23)/malignant lymphoma, lymphoblastic type; class 2] from the respective DACH study centers as independent test samples, the classifier makes consistent calls for the quadruplicates, and all testing-data gene expression profiles get the correct call for class 2 (see Fig. 3 in the online Data Supplement). Again, this result underlined the finding that data variation due to different preparation locations had less influence on the generated gene expression profiles than the type of biological sample.
Discussion
In this study, we investigated the robustness, precision, and reproducibility of microarray gene expression profiling. Overall, only a few patient samples failed the complete sample-preparation workflow. For example, one set of chronic myeloid leukemia replicates (sample no. 112) consistently failed the target cRNA-yield amount at all 4 laboratories. The replicates also had poor values for the percentage of probe sets called as present and for scaling factors. When we examined the patient record in more detail, it became clear that the shipment period for this particular sample was 5 days, from bone marrow biopsy to entry into the laboratory. Although diagnostic signatures have been reported to be robust and stable after 24 h of shipment time for samples of certain types of acute leukemias (17 ) , further investigations of more types of hematologic malignancies will be required to define clear limits for sample-shipment times. Because most hematologic diagnostic centers are open at least 6 days a week, a limit of 48 h between the time of biopsy and receipt of the sample seems reasonable as a criterion for entry into the microarray sample-preparation workflow. With regard to other preparation failures, we noted no other obvious correlations with respect to sample type, laboratory, or operator. Given that many preparations failed in only one laboratory and that we generally prepared samples in batches of 8 with the same master mixes, one can only speculate about the reasons for these rare failures. Some of these preparations failed only at the level of cRNA yield. In this study, the cRNAyield cutoff value was set rather stringently at 8.0 g; however, many of the samples with low cRNA yields still demonstrated acceptable percentages of genes called as present and acceptable scaling factors (sample nos. 4, 46, 102, 109, 113, 122, and 146). Thus, this finding indicates that multiple variables need to be factored into a conclusion on whether a sample is suitable for hybridization to a microarray and whether the generated microarray data can be used for classification analysis.
With respect to the available data on interlaboratory comparability and reproducibility of gene expression signatures, a few studies will be mentioned briefly. To examine the imprecision among replicates from a given tissue sample, Dobbin et al. designed a study of selected lung adenocarcinoma tumor cell lines, extracted samples of tumor RNA, and 12 large and histologically homogeneous tissue samples (predominantly tumors) (37 ) . Sample replicates were randomized and distributed to 4 different laboratories for subsequent processing and microarray analysis. The comparability between laboratories seemed generally lower than within laboratories for all 3 sample types; however, the loss in comparability seemed to be fairly minor, and high intralaboratory and interlaboratory correlations were observed overall. Second, data from the MicroArray Quality Consortia (MAQC), a community-wide effort initiated and led by US Food and Drug Administration scientists and involving 137 participants from 51 organizations, demonstrated promising results with respect to the consistency of microarray data (38 ) . The results demonstrated both intraplatform consistency within and across multiple test sites and a high level of interplatform concordance with respect to the genes identified as differentially expressed in different RNA samples. More recently, Dumur et al. investigated the interlaboratory performance of a novel microarraybased gene expression test to determine the tissue of origin in poorly differentiated and undifferentiated cancers (39 ) . In this study, multiple laboratories were recruited to analyze replicate portions of various tumor tissues. Interestingly, even without standardizing preanalytical conditions, such as reagents for sample preparation, instrumentation, and protocols, cross-laboratory comparisons showed highly reproducible results.
In conclusion, the high number of successful sample preparations and the high-quality microarray data we obtained from technical quadruplicates confirmed that microarrays can offer consistent objective diagnostic test results once a standardized protocol has been established and is followed by trained operators. This study is a first step toward the implementation of high-density gene expression microarrays into clinical practice. A larger study is currently under way to address the actual assay performance in terms of classification accuracy, sensitivity, and specificity of a microarray-based stratification of leukemia subtypes (32 ) .
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